MedTrace Logo

Buprenorphine HIV Care Integration Project

NCT00348868 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2008-03-18

No results posted yet for this study

Summary

A007 is a randomized, two-arm study evaluating the effectiveness of standard drug addiction counseling with buprenorphine/naloxone to enhanced motivational drug counseling with buprenorphine/naloxone for the treatment for opioid addiction in an integrated and nonintegrated HIV care setting.

Conditions

  • HIV Infection
  • Opioid-Related Disorders

Interventions

BEHAVIORAL

enhanced behavioral motivation counseling

BEHAVIORAL

Motivational counseling

BEHAVIORAL

Standard counseling

Sponsors & Collaborators

  • HRSA/Maternal and Child Health Bureau

    collaborator FED

  • National Institute on Drug Abuse (NIDA)

    collaborator NIH

  • University of Miami

    lead OTHER

Principal Investigators

  • Margaret Fischl, M.D. · University of Miami

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-07-31
Primary Completion
2007-12-31
Completion
2007-12-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00348868 on ClinicalTrials.gov